Histogenics Proposes $65M IPO )HealthPointCapital)
Histogenics Corporation filed an S-1 to raise up to $65 million through an initial public offering (IPO) of common shares. The price range and number of shares to be sold in the offering has not yet been determined.
Histogenics' principal stockholders Sofinnova Venture Partners, Split Rock Partners and Wilmslow Estates Limited, have indicated an interest in purchasing an aggregate of up to $15 million of common stock through this offering. Furthermore, Intrexon Corporation, which holds a convertible promissory note in the principal amount of $10 million that will convert into common stock through this IPO, has indicated an interest in purchasing up to an additional $15 million in this offering as well.
The company plans to use the proceeds primarily to develop and advance its regenerative medicine platform, NeoCart, through a Phase 3 clinical trial, to build a new manufacturing facility, and for working capital and general corporate purposes.
Histogenics is biologics company that develops regenerative medicine products for the treatment musculoskeletal-related conditions. The company offers NeoCart, a cartilage-like implant for tre...
